P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
Title:
P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
Author:
Ravandi, Farhad Carraway, Hetty Khouri, Jack Kishtagari, Ashwin Curran, Emily Schiller, Gary Yadav, Bhagyashree (Kelshikar) Morris, Steve Cacovean, Alex Mourya, Sanchita Butler, Thomas Lancet, Jeffrey